Premium
Antitumour necrosis factor‐α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013
Author(s) -
Sbidian E.,
Hotz C.,
Seneschal J.,
Maruani A.,
Amelot F.,
Aubin F.,
Paul C.,
Beylot Barry M.,
Humbert P.,
Dupuy A.,
Caux F.,
Dupin N.,
Modiano P.,
Lepesant P.,
IngenHouszOro S.,
Mahé E.,
Bachelez H.,
Chosidow O.,
Wolkenstein P.
Publication year - 2016
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.14199
Subject(s) - hidradenitis suppurativa , medicine , adalimumab , infliximab , etanercept , dermatology , randomized controlled trial , placebo , surgery , tumor necrosis factor alpha , disease , oncology , pathology , alternative medicine
International audienceHidradenitis suppurativa (HS) is a frequent chronic inflammatory skin disease typically characterized by recurrent painful, deep inflammatory nodules of the axillary, breast, groin and gluteal areas. European recommendations are mainly based on expert opinion. Drug treatments are heterogenous (e.g., antibiotics, corticosteroids, retinoids) and lack consensus among expert centres. The most severe disease forms or those failing to respond to conventional drugs may be associated with worsened functional prognosis. Anti-tumor necrosis factor α (anti-TNFα) drugs have been prescribed in these cases. The results of randomized controlled trials (RCTs) are discordant. Three RCTs concluded to the efficacy of adalimumab (ADA), and two others did not detect any difference between infliximab (IFX) or etanercept (ETA) and placebo. Finally, data from the literature and reported experiences do not conclude on the efficacy of anti-TNFα drugs for HS. This article is protected by copyright. All rights reserve